



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Wednesday, November 25, 2009

Adolor Corporation

[View the current Adolor Corporation Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/130-Adolor+Corporation.html)

(<http://www.bioportfolio.com/biocorporate/130-Adolor+Corporation.html>)

Contact Details:

620 Pennsylvania Drive

Exton

19341

United States of America

Tel: 484 595 1500

Fax: 484 595 1520

Email: adolor@adolor.com

Adolor Corporation is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel prescription pain management products. Adolor's mission addresses a simple goal: to provide enhanced relief for the millions of people who suffer from pain each year. Adolor commenced operations in 1994 and was listed on NASDAQ as ADLR in 2000. Today, the company has almost 200 employees working in areas including discovery research, clinical development, manufacturing, business development, regulatory affairs and marketing. Pain is the most common symptom causing people to seek medical treatment in the United States. More than 25 million people in the United States each year experience chronic moderate-to-severe pain and pain causes more disability than cancer and heart disease combined. The company was founded to capitalize on emerging proprietary development in cloned opioid receptors and continues today as a leader in the discovery and development of novel opioid receptor-targeted therapeutics. Additionally, Adolor's scientific staff is actively assessing other, non-opioid molecular targets. These research efforts work towards developing products that maintain or improve opioid-like pain relief while reducing or eliminating opioid side effects. Entereg® (alvimopan), Adolor's lead product candidate, is a small molecule, a peripherally-acting mu opioid receptor antagonist (PAM-OR) and the first of this class. Entereg is designed to inhibit the adverse side effects of opioid analgesics on the GI tract without interfering with their beneficial analgesic effects. Entereg is currently in late stage development to manage postoperative ileus, a negative gastrointestinal side effect following bowel resection surgery. Entereg is also being developed to manage negative GI side effects associated with opioid use. These side effects can negatively impact quality of life for millions of patients using opioid analgesic products, such as morphine, to treat pain. Adolor is collaborating with GlaxoSmithKline (GSK) for the development and commercialization of Entereg for POI and OBD. By applying its knowledge and expertise in pain management, along with ingenuity, Adolor Corporation is seeking to make a positive difference for patients, caregivers, and the medical community.

- [Novel sulfamoyl benzamides as selective CB\(2\) agonists with improved in vitro metabolic stability.](#)
*A lead optimization campaign in our previously reported sulfamoyl...*19th November, 2009
Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive,- Bioorg Med Chem Lett. 2009 Oct 17. ([DOI Direct Link](#))
- [Medicinal chemistry strategies to reduce CYP2D6 inhibitory activity of lead candidates.](#)
*Among the various human cytochrome P450s (CYP450s) that catalyze the...*7th November, 2009
Department of Chemistry, Adolor Corporation, Exton, PA 19341, USA.- Curr Med Chem. 2009;16(24):3093-121.
- [Simultaneous optimization of potency, selectivity and physicochemical properties for cannabinoid CB\(2\) ligands.](#)
*Non-selective cannabinoid ligands display a wide range of physiological...*29th October, 2009
Department of Chemistry, Adolor Corporation, Exton, PA 19341, USA.- Curr Pharm Des. 2009;15(29):3345-66.
- [Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-\(spiro\[chromene-2,4'-piperidine\]-4-yl\) benzamide \(ADL5747\).](#)
*Selective, nonpeptidic delta opioid receptor agonists have been the...*15th October, 2009
Departments of Chemistry, Adolor Corporation, 700 Pennsylvania Drive,- J Med Chem. 2009 Sep 24;52(18):5685-702. ([DOI Direct Link](#))
- [High-performance liquid chromatographic enantioseparation of methanobenzazocines.](#)
*Chiral recognition and resolution of methanobenzazocines was investigated...*6th October, 2009
Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive,- J Chromatogr A. 2009 Nov 6;1216(45):7708-14. Epub 2009 Aug 18. ([DOI Direct Link](#))
- [Novel pyridine derivatives as potent and selective CB2 cannabinoid receptor agonists.](#)
*Replacement of the phenyl ring in our previous (morpholinomethyl)aniline...*9th September, 2009
Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive,- Bioorg Med Chem Lett. 2009 Oct 15;19(20):5931-5. Epub 2009 Aug 21. ([DOI Direct Link](#))
- [Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208.](#)
*Cyclic tetrapeptide c[Phe-pro-Phe-trp] 2, a diastereomer of CJ-15,208 (1),...*2nd September, 2009
Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive,- Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50. Epub 2009 May 3. ([DOI Direct Link](#))
- [Comprehensive survey of chemical libraries for drug discovery and chemical biology: 2008.](#)
*Replacement of the phenyl ring in our previous (morpholinomethyl)aniline...*1st September, 2009
Adolor Corporation, 700 Pennsylvania Drive, Exton, Pennsylvania 19341,- J Comb Chem. 2009 Sep-Oct;11(5):739-90. ([DOI Direct Link](#))
- [Discovery of N-\(3-\(morpholinomethyl\)-phenyl\)-amides as potent and selective CB2 agonists.](#)
*Recently sulfamoyl benzamides were identified as a novel series of...*4th August, 2009
Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive,- Bioorg Med Chem Lett. 2009 Sep 1;19(17):5004-8. Epub 2009 Jul 12. ([DOI Direct Link](#))
- [CB2 selective sulfamoyl benzamides: optimization of the amide functionality.](#)
*Previous research within our laboratories identified sulfamoyl benzamides...*3rd March, 2009
Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive,- Bioorg Med Chem Lett. 2009 Jan 15;19(2):309-13. Epub 2008 Nov 27. ([DOI Direct Link](#))
- [Comprehensive survey of chemical libraries for drug discovery and chemical biology: 2007.](#)
*Previous research within our laboratories identified sulfamoyl benzamides...*1st January, 2009
Adolor Corporation, 700 Pennsylvania Drive, Exton, Pennsylvania 19341,- J Comb Chem. 2008

Nov-Dec;10(6):753-802. ([DOI Direct Link](#))

- [Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-\(5-hydroxyspiro\[chromene-2,4'-piperidine\]-4-yl\)benzamide \(ADL5859\).](#)
*Selective delta opioid receptor agonists are promising potential...*31st October, 2008
Department of Chemistry, Adolor Corporation, Exton, Pennsylvania 19341,- J Med Chem. 2008 Oct 9;51(19):5893-6. Epub 2008 Sep 13. ([DOI Direct Link](#))
- [Use of receptor chimeras to identify small molecules with high affinity for the dynorphin A binding domain of the kappa opioid receptor.](#)
*A series of 2-substituted sulfamoyl arylacetamides of general structure 2...*30th August, 2008
Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA.- Bioorg Med Chem Lett. 2008 Jun 15;18(12):3667-71. Epub 2007 Dec 4. ([DOI Direct Link](#))
- [Sulfamoyl benzamides as novel CB2 cannabinoid receptor ligands.](#)
*Sulfamoyl benzamides were identified as a novel series of cannabinoid...*17th July, 2008
Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive,- Bioorg Med Chem Lett. 2008 May 1;18(9):2830-5. Epub 2008 Apr 7. ([DOI Direct Link](#))
- [Novel trans-3,4-dimethyl-4-\(3-hydroxyphenyl\)piperidines as mu opioid receptor antagonists with improved opioid receptor selectivity profiles.](#)
*A series of N-substituted...*10th June, 2008
Department of Chemistry, Adolor Corporation, 700 Pennsylvania Drive,- Bioorg Med Chem Lett. 2008 Mar 15;18(6):2006-12. Epub 2008 Feb 2. ([DOI Direct Link](#))

Press Releases on Adolor Corporation:

[FDA Accepts Once](#)

[Daily 23 mg Aricept\(R\) Extended Release NDA for Review](#) 24th November, 2009

Eisai Inc.

WOODCLIFF LAKE, N.J. and NEW YORK, Nov. 24 /PRNewswire/ -- Eisai Inc. and Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's New Drug PLYMOUTH MEETING, Pa., Nov. 24 /PRNewswire-Asia-FirstCall/ --

[BMP Sunstone to Present at Piper Jaffray Health Care Conference](#)

24th November, 2009

BMP Sunstone Corporation

BMP Sunstone Corporation (Nasdaq: BJGP) ("BMP Sunstone" or the "Company") today announced that the Company will

[BioMarin to Present at the NASDAQ OMX 23rd Investor Program](#)

24th November, 2009

BioMarin Pharmaceutical Inc.

NOVATO, Calif., Nov. 24 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company

[Centene Corporation Receives Notification of Intent to Contract From the State of Mississippi](#)

24th November, 2009

Centene Corporation

ST. LOUIS, Nov. 24 /PRNewswire-FirstCall/ -- Centene Corporation (NYSE: CNC) today announced that the Mississippi Division of Medicaid has selected Centene as one of two Coordinated Care Organizations

[Sigma-Aldrich to Present at the NASDAQ OMX 23rd Investor Program on Tuesday, December 1, 2009](#)

24th November, 2009 Sigma-Aldrich Corporation

ST. LOUIS, Nov. 24 /PRNewswire-FirstCall/ -- Sigma-Aldrich Corporation (Nasdaq: SIAL) will be presenting at the NASDAQ OMX conference on Tuesday, December 1st at 1:45 PM GMT in London, 7:45 AM US/CST.

BioNews Results for Adolor Corporation



- [Webcast Auction Today with Great Deals on Lab/Pharma Equipment](#)
PRWeb: Nov 17 2009 8:14AM Matching: adolor
- [Adolor begins clinical test of oral mu opioid receptor antagonist for OBD treatment](#)
PharmaBiz: Nov 14 2009 6:04AM Matching: adolor
- [Adolor Corporation Initiates Clinical Testing in Opioid Bowel Dysfunction Program](#)
Pharma Live: Nov 14 2009 1:00AM Matching: adolor
- [Adolor commences clinical testing of its oral mu opioid receptor antagonist](#)
News-Medical.Net: Nov 13 2009 6:13AM Matching: adolor
- [Adolor Corporation Initiates Clinical Testing in Opioid Bowel Dysfunction Program](#)
MDLinx: Nov 13 2009 11:07AM Matching: adolor
- [Webcast Auction Today with Great Deals on Lab/Pharma Equipment](#)
Earthtimes.org: Nov 12 2009 3:24PM Matching: adolor
- [Adolor Corporation Initiates Clinical Testing in Opioid Bowel Dysfunction Program](#)
Street Insider: Nov 12 2009 2:20PM Matching: adolor
- [Adolor Corporation Initiates Clinical Testing in Opioid Bowel Dysfunction Program](#)
Business Wire UK: Nov 12 2009 2:17PM Matching: adolor
- [Adolor Corporation Initiates Clinical Testing in Opioid Bowel Dysfunction Program](#)
PR inside: Nov 12 2009 7:50PM Matching: adolor
- [Adolor Corporation Initiates Clinical Testing in Opioid Bowel Dysfunction Program](#)
PR inside: Nov 12 2009 7:48PM Matching: adolor
- [Adolor Corporation Initiates Clinical Testing in Opioid Bowel Dysfunction Program](#)
Genetic Engineering News: Nov 12 2009 2:55PM Matching: adolor
- [Adolor Corporation Initiates Clinical Testing in Opioid Bowel Dysfunction Program](#)
FinanzNachrichten.de: Nov 12 2009 2:18PM Matching: adolor
- [Adolor Corporation Initiates Clinical Testing in Opioid Bowel Dysfunction Program](#)
Yahoo! Canada: Nov 12 2009 4:24PM Matching: adolor
- [Adolor Corp. Q3 2009 Earnings Conference Call](#)
Seeking Alpha: Oct 29 2009 3:34PM Matching: adolor
- [Adolor Corporation Reports Third Quarter 2009 Financial Results](#)
FinanzNachrichten.de: Oct 29 2009 12:14PM Matching: adolor

Adolor Corporation Clinical Trials:



- [Study of Alvimopan for the Management of Opioid-Induced Postoperative Bowel Dysfunction/Postoperative Ileus](#)

Adolor Corporation Patents:



- 5667773- [Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic conditions therewith](#)
- 6004964- [Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith](#)
- 6028063- [Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith](#)
- 6048860- [Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith](#)
- 6054445- [Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith](#)
- 6057323- [Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith](#)
- 6180623- [Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith](#)
- 6190691- [Methods for treating inflammatory conditions](#)
- 6239154- [Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith](#)
- 6303611- [Kappa agonist compounds and pharmaceutical formulations thereof](#)
- 6353004- [Peripherally acting anti-pruritic opiates](#)
- 5981513- [Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith](#)
- 5962477- [Screening methods for cytokine inhibitors](#)
- 5688955- [Kappa agonist compounds and pharmaceutical formulations thereof](#)
- 5744458- [Kappa agonist compounds and pharmaceutical formulations thereof](#)
- 5760023- [Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith](#)
- 5763445- [Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith](#)
- 5798093- [Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions and pruritus therewith](#)
- 5811078- [Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions therewith](#)

- 5849762- [Peripherally acting anti-pruritic opiates](#)
- 5869521- [Kappa agonist anti-pruritic pharmaceutical formulations and method of treating pruritus therewith](#)
- 5888494- [Film-forming compositions of antihyperalgesic opiates and method of treating hyperalgesic and pruritic conditions therewith](#)
- 5945443- [Kappa agonist compounds and pharmaceutical formulations thereof](#)
- 6391910- [Kappa agonist compounds and pharmaceutical formulations thereof](#)
- 6451806- [Methods and compositions involving opioids and antagonists thereof](#)
- 6469030- [Methods for the treatment and prevention of ileus](#)
- 7087749- [Substituted piperidine compounds and methods of their use](#)
- 7091354- [Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto](#)
- 7160902- [Amide derivatives and methods of their use](#)
- 7294647- [Kappa agonist compounds and pharmaceutical formulations thereof](#)
- 7297796- [Sulfamoyl benzamide derivatives and methods of their use](#)
- 7338962- [Spirocyclic heterocyclic derivatives and methods of their use](#)
- 7381721- [Substituted piperidine compounds](#)
- 7538110- [Opioid antagonists](#)
- 7544676- [Sulfamoyl benzamides and methods of their use](#)
- 7576207- [Spirocyclic heterocyclic derivatives and methods of their use](#)
- 7034051- [Fused bicyclic carboxamide derivatives and methods of their use](#)
- 6992193- [Sulfonylamino phenylacetamide derivatives and methods of their use](#)
- 6476063- [Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith](#)
- 6486165- [Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith](#)
- 6492351- [Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith](#)
- 6573282- [Peripherally active anti-hyperalgesic opiates](#)
- 6630462- [Delta agonist analgesics](#)
- 6750216- [Kappa agonist compounds and pharmaceutical formulations thereof](#)
- 6794510- [Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto](#)
- 6852713- [Lactam derivatives and methods of their use](#)
- 6960612- [Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith](#)
- 6992090- [Substituted piperidine compounds and methods of their use](#)
- 7598261- [Spirocyclic heterocyclic derivatives and methods of their use](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo

- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

